PT  - JOURNAL ARTICLE
AU  - Torokaa, Peter Richard
AU  - Kileo, Heledy
AU  - Urio, Loveness
AU  - Mbwana, Mariam R.
AU  - Monah, Mariam C.
AU  - Ntibabara, Sephord Saul
AU  - Kimambo, Jasper
AU  - Seleman, Paschal
AU  - Franklin, Collins
AU  - Balama, Robert
AU  - Kisonga, Riziki M.
AU  - Majigo, Mtebe V.
AU  - Joachim, Agricola
TI  - The Pattern of rpoB gene mutation of <em>Mycobacterium tuberculosis</em> and predictors of rifampicin resistance detected by gene Xpert MTB/Rif in Tanzania
AID  - 10.1101/2023.12.23.23300496
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.23.23300496
4099  - http://medrxiv.org/content/early/2023/12/28/2023.12.23.23300496.short
4100  - http://medrxiv.org/content/early/2023/12/28/2023.12.23.23300496.full
AB  - Introduction Antimicrobial resistance associated with Mycobacterium tuberculosis (MTB) is the challenge facing Tuberculosis (TB) management worldwide. Rifampicin resistance (RR) has been associated with the rpoB gene mutation. No study was conducted in Tanzania to determine the commonest mutation. The inconsistent findings from various studies support the need to determine whether reported mutation patterns are applicable in our setting. We determined the frequency of rpoB gene mutation and factors associated with RR detected using GeneXpert MTB/Rif.Methods We conducted a retrospective cross-sectional study involving data from the National Tuberculosis and Leprosy Program database from 2020 to 2022 for cases investigated using GeneXpert. Descriptive analysis was performed as the frequency for categorical variables. The chi-square test and regression analysis assessed the relationship between the independent variables and outcome. The 95% confidence interval and a significance level of p<0.05 were used to assess the association strength.Results A total of 56,004 participants had status of MTB and RR. Most, 38,705/56,004 (69.11%) were male. Probe E, 89/219 (40.64%) was the predominant. Human immunodeficiency virus (HIV)-positive patients had a higher gene mutation, 134/10601 (1.26%) than HIV-negative, 306/45016 (0.68%) (p<0.001). Patients with both pulmonary and extra-pulmonary TB had about four times greater odds of developing rifampicin resistance (AOR 3.88, 95%CI: 1.80 – 8.32). RR was nearly nine times higher in previously treated patients than new patients (AOR 8.66, 95%CI: 6.97–10.76). HIV-positive individuals had nearly twice the odds of developing RR than HIV-negative individuals (AOR 1.91, 95%CI: 1.51 – 2.42).Conclusion The rate of RR was low compared to other studies in Tanzania, with probe E mutations the most prevalent. Patients with disseminated TB, HIV co-infection and those with prior exposure to anti-TB had more risk of RR. The findings highlight the need to strengthen surveillance of multidrug-resistant-TB among patients with a higher risk of RR.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Senate Research and Publications Committee of Muhimbili University of Health and Allied Sciences Ref. No. DA.282/298/01L/629 gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors